ABC News medical correspondent Dr. Darien Sutton explains how Tzield works to delay type 1 diabetes progression, who is ...

Treatment with teplizumab significantly slowed the decrease in mean C-peptide levels, a marker of beta cell function, compared with placebo. The Food and Drug Administration (FDA) has granted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Z.ai has launched ZCode, a free AI coding tool powered by GLM-5.2 that challenges Cursor, Claude Code and GitHub Copilot ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for a potential approval under a controversial new pathway, the FDA has ...

Despite some back-and-forth with the U.S. FDA regarding inclusion in the somewhat controversial Commissioner’s National Priority Voucher (CNPV) program, Sanofi SA’s Tzield (teplizumab) gained FDA ...

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerated approval in children aged eight to 17 years old ...

Z.ai’s GLM-5.2 is an open-source model aimed at long-context coding-agent workflows, with support for a one million-token ...

Sanofi secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 ...

Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production Approval based on the PROTECT phase 3 study and ...